FTO is involved in chemotherapy resistance in various tumor types, including colorectal cancer (Lin et al., 2023a; Wang et al., 2022b), breast cancer (Ou et al., 2022; Wang et al., 2021), acute myeloid leukemia (Zhang et al., 2023), gastric cancer (Liu et al., 2023), and glioblastoma (Li et al., 2021). This evidence concerns the gene FTO and breast cancer.